Joel Skoletsky

2.7k total citations · 1 hit paper
13 papers, 1.7k citations indexed

About

Joel Skoletsky is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Joel Skoletsky has authored 13 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Joel Skoletsky's work include Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (5 papers) and Cystic Fibrosis Research Advances (3 papers). Joel Skoletsky is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (5 papers) and Cystic Fibrosis Research Advances (3 papers). Joel Skoletsky collaborates with scholars based in United States, France and Poland. Joel Skoletsky's co-authors include Anthony P. Shuber, Kevin A. Boynton, David A. Ahlquist, Jonathan J. Harrington, Douglas W. Mahoney, William E. Pierceall, Stephen N. Thibodeau, K. Klinger, Rosemary Balfour and Robert C. Stern and has published in prestigious journals such as Gastroenterology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Joel Skoletsky

12 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin

2020 265 citations Meijuan Li, Jason D. Hughes et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Skoletsky United States	10	760	702	635	462	457	13	1.7k
Amy M. Fowler United States	22	558 0.7×	327 0.5×	283 0.4×	459 1.0×	220 0.5×	88	1.7k
Erika M. Kwon United States	25	269 0.4×	729 1.0×	316 0.5×	388 0.8×	800 1.8×	48	1.9k
Yanxin Luo China	26	892 1.2×	865 1.2×	368 0.6×	491 1.1×	361 0.8×	88	2.0k
Mandy L. Ballinger Australia	25	364 0.5×	772 1.1×	158 0.2×	428 0.9×	237 0.5×	102	1.8k
Karey Shumansky Canada	15	369 0.5×	495 0.7×	345 0.5×	243 0.5×	268 0.6×	20	1.3k
Angelica A. Saetta Greece	25	472 0.6×	826 1.2×	260 0.4×	346 0.7×	262 0.6×	79	1.7k
Cindy A. Eads United States	9	395 0.5×	2.2k 3.1×	337 0.5×	417 0.9×	243 0.5×	10	2.6k
Anthony Rhodes United Kingdom	21	1.0k 1.4×	758 1.1×	168 0.3×	696 1.5×	205 0.4×	47	1.8k
Maria Teresa Del Vecchio Italy	25	889 1.2×	509 0.7×	342 0.5×	172 0.4×	278 0.6×	71	1.9k
Manuel Sánchez‐Chapado Spain	24	264 0.3×	560 0.8×	219 0.3×	238 0.5×	646 1.4×	94	1.7k

Countries citing papers authored by Joel Skoletsky

Since Specialization

Citations

This map shows the geographic impact of Joel Skoletsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Skoletsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Skoletsky more than expected).

Fields of papers citing papers by Joel Skoletsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Skoletsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Skoletsky. The network helps show where Joel Skoletsky may publish in the future.

Co-authorship network of co-authors of Joel Skoletsky

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Skoletsky. A scholar is included among the top collaborators of Joel Skoletsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Skoletsky. Joel Skoletsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Huang, Richard S.P., Michelle Green, Andrej Savol, et al.. (2025). Analytical validation (accuracy, reproducibility, limit of detection) and gene expression analysis of FoundationOneRNA assay for fusion detection in 189 clinical tumor specimens. PLoS ONE. 20(9). e0329697–e0329697.

Dziadziuszko, Rafał, Tiffany Hung, Kun Wang, et al.. (2022). Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib. Molecular Oncology. 16(10). 2000–2014. 11 indexed citations

Dziadziuszko, Rafał, Fabrice André, Wesley Yip, et al.. (2020). 1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib. Annals of Oncology. 31. S785–S786. 4 indexed citations

Li, Meijuan, Jason D. Hughes, Joel Skoletsky, et al.. (2020). Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 15(9). e0237802–e0237802. 265 indexed citations breakdown →

Yip, Wai‐Ki, Joel Skoletsky, Pei Ma, et al.. (2018). Abstract 1607: An ERBB2 follow-on companion diagnostic for clinical care of patients with breast cancer. Cancer Research. 78(13_Supplement). 1607–1607. 1 indexed citations

Itzkowitz, Steven H., Lina Jandorf, Randall E. Brand, et al.. (2006). Improved Fecal DNA Test for Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology. 5(1). 111–117. 192 indexed citations

Chen, Wei-Dong, Zhifen Han, Joel Skoletsky, et al.. (2005). Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene. JNCI Journal of the National Cancer Institute. 97(15). 1124–1132. 283 indexed citations

Whitney, Duncan, Joel Skoletsky, Kevin A. Boynton, et al.. (2004). Enhanced Retrieval of DNA from Human Fecal Samples Results in Improved Performance of Colorectal Cancer Screening Test. Journal of Molecular Diagnostics. 6(4). 386–395. 59 indexed citations

Ahlquist, David A., Joel Skoletsky, Kevin A. Boynton, et al.. (2000). Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology. 119(5). 1219–1227. 399 indexed citations

10.

Shuber, Anthony P., et al.. (1997). High Throughput Parallel Analysis of Hundreds of Patient Samples for More Than 100 Mutations in Multiple Disease Genes. Human Molecular Genetics. 6(3). 337–347. 53 indexed citations

11.

Bianchi, Diana W., et al.. (1996). DEVELOPMENT OF A MODEL SYSTEM TO COMPARE CELL SEPARATION METHODS FOR THE ISOLATION OF FETAL CELLS FROM MATERNAL BLOOD. Prenatal Diagnosis. 16(4). 289–298. 46 indexed citations

12.

Richards, Brenda, Joel Skoletsky, Anthony P. Shuber, et al.. (1993). Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Human Molecular Genetics. 2(2). 159–163. 343 indexed citations

13.

Shuber, Anthony P., et al.. (1993). Efficient 12-mutation testing in the CFTR gene: a general model for complex mutation analysis. Human Molecular Genetics. 2(2). 153–158. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact